Novartis CEO Joseph Jimenez Stepping Down; Company Names Vasant Narasimhan Next CEO

September 8, 2017: By Jon Swedien
Vasant Narasimhan (left) and Joseph Jimenez (second to the right)

Vasant Narasimhan (left) and Joseph Jimenez (second from left)

Joseph Jimenez will step down as the CEO of Novartis effective Jan. 31, 2018, the Swiss company announced Sept. 4.

The company’s board of directors has appointed Vasant Narasimhan, MD, to be Jimenez’ replacement effective Feb. 1, 2018.

Jimenez said his stepping down won’t affect an ongoing review of Alcon.

“We’re going to consider all options ranging from keeping the business up to a capital markets exit,” Jimenez said after his upcoming departure was announced, Reuters reported.

Jimenez has said Novartis will give an update toward the end of the year on Alcon’s future.

In July, Alcon’s net sales grew 1 percent in Q2-2017, and Jimenez said the positive results increased his options if he were to move toward spinning out Alcon.

After Jimenez steps down in January, he will stay on with Novartis until his scheduled retirement on Aug. 31, 2018, the company said. Jimenez will be available for advice and support at the request of Novartis’ chairman or CEO until he retires.

Jimenez joined the company in 2007. He has been CEO since 2010. Before becoming CEO, Jimenez led Novartis’ consumer health division and then held the position of division head, Novartis Pharmaceuticals.

Narasimhan, a US citizen who lives in Switzerland, is currently Novartis’ global head of drug development and chief medical officer.

He joined Novartis in 2005 and is a member of its executive committee. He has held numerous leadership positions in commercial, drug development, and strategy roles, the company said. Prior to his current role, he served as head of development for Novartis Pharmaceuticals.

While Narasimhan and Jimenez were both appointed to CEO from within Novartis’ ranks, they have considerably different backgrounds.

Jimenez came to Novartis from the consumer goods industry, having worked at Clorox and H.J. Heinz. He graduated with an economics degree from Stanford University in 1982 and earned his MBA in 1984 from the University of California, Berkeley.

Narasimhan received his medical degree from Harvard Medical School and obtained a master’s degree in public policy from Harvard’s John F. Kennedy School of Government. He also holds a bachelor’s degree in biological sciences from the University of Chicago.

Narasimhan started his career as a consultant at McKinsey & Company, a global management consulting firm.

He is the third CEO in Novartis’ history. The first was Daniel Vasella, MD, who was appointed CEO in 1996, when Ciba-Geigy merged with Sandoz to form Novartis. Before joining Novartis, Vasella held a number of medical positions in Switzerland.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Advisory Panel to Review Aerie’s Rhopressa in October

Johnson & Johnson Vision Acquires Online Contact Lens Business Sightbox

Novartis Returns OUS Rights for Jetrea to ThromboGenics

Eyevance Licenses Zerviate from Nicox for US Commercialization

Two Eye Projects Fail to Make Final Round for $100M Grant

Ophthotech Begins Phase IIa Trial for Zimura in Wet AMD

Graybug Vision Begins Phase I/II Trial for Candidate in Wet AMD

BioTime Receives $1.56 Million NIH Grant to Advance OpRegen for Dry AMD

FDA Approves Mvasi, a Biosimilar of Avastin Co-developed by Amgen, Allergan

Carl Zeiss Meditec Launches Zeiss Clarus 500 Ultra-Widefield Fundus Imaging System in US

Imprimis Appeals to Public Sentiment in Fiery Response to Allergan Lawsuit

Roche’s Lampalizumab Fails in Phase III Study in Geographic Atrophy

Aldeyra Reports Positive Phase IIa Results for Dry Eye Candidate ADX-102

US Denies Coherus’ Petitions Challenging AbbVie’s Patent for Humira

Ocular Therapeutix Names Michael Goldstein, MD, Chief Medical Officer

PhysIOL Agrees to Acquire Majority Stake in Italian Optikon

Rayner Creates US Subsidiary in New York

Inotek to Merge with Gene Therapy Startup Rocket

Allergan Agrees to $13.75 Million Deal with Tribe to Protect Restasis Patents

Ellex to Boost Production of iTrack Microcatheters to 50 Thousand a Year

Coming soon

2017 Retinal Pharmaceuticals and Biologics Report: A Global Market Analysis for 2016 to 2022